Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14257MR)

This product GTTS-WQ14257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3440MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ10823MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ2870MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ7646MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ15274MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ5598MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ426MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ8385MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW